Elsafi Salah H, Almutairi Saleh H, Alsulaimani Mujahid A, AlBahrani Salma, Al-Maqati Thekra N, Alanazi Wafa K, Alanazi Mohammed N, Alamri Abdullah A, Alkhathami Majed Hamoud, Alshammari Rakkad A, Alharbi Naif F, Al Naam Yaser A
Clinical Laboratory Sciences. Prince Sultan Military College of Health Sciences, Dhahran, Saudia Arabia.
Pharmacy Services Department, King Fahad Military Medical Complex, Dhahran, Saudi Arabia.
Infect Drug Resist. 2024 Jun 4;17:2227-2236. doi: 10.2147/IDR.S460148. eCollection 2024.
Earlier reports suggested high rates of antibiotic utilization among COVID-19 patients despite the lack of direct evidence of their activity against viral pathogens. Different trends in antibiotic consumption during 2020 compared to 2019 have been reported.
The objective of this study is to assess the impact of COVID-19 pandemic on antibiotic consumption in the presence of active Antibiotic Stewardship Program.
This study represented a five years assessment of the consumption of the commonly prescribed antibiotics measured as DDDs/100-Bed Days. We analyzed the data by using nonparametric Friedman and Friedman tests to compare the antibiotic consumption before and during the three subsequent waves of COVID-19.
Antibiotic consumption through the DDDs/100-BD has shown reduction in the median of antibiotics consumption of most antibiotics during the period of COVID-19 as compared to the pre-COVID-19 period, which was significant for meropenem and ciprofloxacin, except colomycin that slightly increased. Significant reduction in the consumption of imipenem and meropenem during the second and third waves as compared to the pre-COVID period. Throughout the years, significant reductions were observed between 2018 and 2019 (p=<.001), 2018 and 2020 (p=0.008), and 2018 and 2022 (p=0.002).
The reduction in antibiotic consumption is attributed to the strong influence if the ASP and the reluctance of people to visit hospitals during the COVID-19 pandemic. Other related COVID-19 precautions such as physical distance, good hand hygiene, facemasks, that resulted in the prevention of secondary bacterial infections have contributed to the reduction in antibiotic utilization during the pandemic.
早期报告显示,尽管缺乏抗生素对病毒病原体有活性的直接证据,但新冠患者中抗生素使用率很高。据报道,2020年与2019年相比抗生素消费有不同趋势。
本研究的目的是评估在有积极的抗生素管理计划的情况下,新冠疫情对抗生素消费的影响。
本研究对常用抗生素的消费情况进行了为期五年的评估,以限定日剂量数(DDDs)/100床日为衡量标准。我们使用非参数Friedman检验和Friedman检验分析数据,以比较新冠疫情前三波期间之前和期间的抗生素消费情况。
与新冠疫情前时期相比,在新冠疫情期间,通过DDDs/100-BD计算的大多数抗生素的中位数抗生素消费量有所减少,美罗培南和环丙沙星的减少幅度显著,除了多粘菌素略有增加。与新冠疫情前时期相比,第二波和第三波期间亚胺培南和美罗培南的消费量显著减少。在整个研究期间,2018年和2019年之间(p<0.001)、2018年和2020年之间(p=0.008)以及2018年和2022年之间(p=0.002)观察到显著减少。
抗生素消费的减少归因于抗生素管理计划的强大影响以及新冠疫情期间人们不愿前往医院。其他相关的新冠疫情预防措施,如保持身体距离、良好的手部卫生、佩戴口罩,这些措施预防了继发性细菌感染,有助于在疫情期间减少抗生素的使用。